

IQnovate Share Placement Completed

12 March 2013

IQnovate Limited (NSX: IQN ,OTC:IQNDY) is pleased to announce that the share placement it commenced on $30^{\rm th}$ October 2012 has been completed after strong interest was received from investors.

The company intends to use the net proceeds to further expand its business opportunities.

Mr George Syrmalis, CEO of IQnovate, said: "Our unique business model of becoming the world's first IP asset management company for the biopharma industry is raising a considerable amount of interest, and we need to be in a position to take advantage of that, either through organic growth or M&A activity"

IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, IQNovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

IQNovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.

IQNovate is publicly listed with the National Stock exchange of Australia - NSX: IQN and cross listed on the OTC in New York USA - OTC: IQNDY